Skip to content

Clinical Efficacy of Xiaoqinglong Decoction in Treatment of Eosinophilic Nasal Polyp and Mechanism of Reducing Th2 Inflammatory Factors

Clinical Efficacy of Xiaoqinglong Decoction in Treatment of Eosinophilic Nasal Polyp and Mechanism of Reducing Th2 Inflammatory Factors

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100005008
Enrollment
Unknown
Registered
2021-07-03
Start date
2021-01-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic sinusitis with nasal polyps

Interventions

Sponsors

The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Subjects must voluntarily participate in this study and abide by the study regulations, understand and abide by the medication dosage, follow up plan, correctly record adverse event records, and voluntarily sign the written informed consent; 2. Aged 18 to 70 years old male and female; 3. Diagnostic criteria are based on the CRS diagnostic criteria for nasal polyps associated with "European Guidelines for the Diagnosis and Treatment of Rhinosinusitis and Nasal Polyps 2020". This included subjective evaluation, endoscopy and imaging examination of patients; 4. Patients with VAS score 3 to 7 and polyps >=1 in Lund-Kennedy score of nasal endoscopy; 5. The mucosal tissues of nasal polyps were stained with HE. At high magnification, eosinophils >=10% of total inflammatory cells.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Subjects had cystic fibrosis, congenital ciliary dyspraxia, non-invasive fungal balls and invasive mycosis, systemic vasculitis and granulomatous disease, tumor patients, immunodeficiency, and allergic fungal sinusitis; 3. The subject is allergic to hormones; 4. Subjects with other autoimmune diseases are receiving long-term immunosuppressive drug therapy; 5. Subjects are suffering from respiratory tract infection; 6. Clinically serious metabolic, cardiovascular, immune, neurological, hematological, digestive, cerebrovascular, or respiratory diseases, or any disease considered by the Investigator to interfere with the evaluation of study results or affect the safety of subjects; 7. Currently participating in other clinical studies or participating in other clinical investigators within 30 days, or directly participating in the study staff; 8. Having a history of mental illness, antagonistic personality, bad motivation, paranoia or other emotional or intellectual problems may affect the informed effectiveness of study participants; 9. Other CRS drugs or other treatments, such as nasal irrigation, were administered topically and systemically during the first 4 weeks of the trial.

Design outcomes

Primary

MeasureTime frame
IL-13;IL-5;IL-4;

Countries

China

Contacts

Public ContactZheng Liu

The First Affiliated Hospital of Guangzhou University of Chinese Medicine

zhengzheng0713@163.com+86 15913123928

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026